Protagonist Therapeutics, Inc (PTGX) stock
PTGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 12/30199% above fair value
$124.67−0.16 (-0.13%)
Close on Nov 17, 2026Market cap $8.07BP/E 121.0Yield –
Protagonist Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Protagonist Therapeutics
Protagonist Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?